¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
UBE(Unilateral Biportal Endoscopy) ½ÃÀå ¼ºÀå ¹× µ¿Çâ:
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é Àü ¼¼°è UBE(Unilateral Biportal Endoscopy) ½ÃÀå ±Ô¸ð´Â 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 6.0%·Î È®´ëµÇ¾î 2030³â±îÁö 13¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÔ¿ø ±â°£ ´ÜÃà, ºÎ¼öÀû Á¶Á÷ ¼Õ»ó ÃÖ¼ÒÈ, ¼ö¼ú ÈÄ ÇÕº´Áõ °¨¼Ò, Á¶±â ȸº¹ µîÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿Ü°úÀÇ»çµé°ú ±×µéÀÇ Áø·á´Â ÀüÅëÀûÀÎ °³º¹ ¼ö¼ú¿¡¼ ·Îº¿ º¸Á¶ ¹× ½Ã°¢ÀûÀ¸·Î Áøº¸µÈ ³»½Ã°æ ¼ö¼ú·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ôÃß ³»½Ã°æ ¼ö¼ú ¹× ÃÖ¼Òħ½À ¼ö¼ú ºÐ¾ßÀÇ ±â¼ú ¹ßÀüÀº ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2017³â 6¿ù ¿Ã¸²Çª½º´Â VISERA ELITE II ½Ã½ºÅÛ°ú ȣȯµÇ´Â 3D ¼ö¼ú¿ë ³»½Ã°æÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Á¦Ç°Àº 3D À̹Ì¡À» »ç¿ëÇÏ¿© ¼ö¼úÀÇ Á¤È®¼ºÀ» ³ôÀ̱â À§ÇØ ±íÀÌ ÀνÄÀ» µ½½À´Ï´Ù.
ÇöÀç ÁøÇà ÁßÀÎ COVID-19 ÆÒµ¥¹ÍÀº Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛ¿¡ ºÎ´ãÀ» ÁÖ°í ÀÖÀ¸¸ç, ³»½Ã°æ °Ë»ç ±â°üÀÌ ¼±ÅÃÀû, ºÒÇÊ¿äÇÑ ³»½Ã°æ ½Ã¼úÀÇ ¾çÀ» ÁÙ¿©¾ß ÇÏ´Â µî ÀÇ·á »ê¾÷¿¡ Å« º¯È¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¼¼°è³»½Ã°æ±â±¸(World Endoscopy Organization)°¡ 2020³â 4¿ùºÎÅÍ 2020³â 5¿ù±îÁö 55°³±¹ÀÇ ³»½Ã°æ °Ë»ç ±â°üÀ» ´ë»óÀ¸·Î ½Ç½ÃÇÑ Á¶»ç¿¡ µû¸£¸é, ³»½Ã°æ °Ë»ç °Ç¼ö°¡ 87.0% °¨¼ÒÇÑ °ÍÀ¸·Î º¸°íµÇ¾ú½À´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ÆÒµ¥¹ÍÀº ¼ö¼ú½Ç ±¸Á¶, ÀηÂ, ÀûÀÀÁõ, ¼ö¼ú Àü Áغñ¿¡ º¯È¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ³»½Ã°æ ¼ö¼úÀÇ ³î¶ó¿î °¨¼Ò´Â ½ÅÈï °æÁ¦ ±¹°¡¿¡¼ ÀÇ·á ½Ã¼³¿¡¼ ±â·ÏµÇ¾ú½À´Ï´Ù.
2021³â¿¡´Â Àç»ç¿ë °¡´ÉÇÑ Á¦Ç° À¯ÇüÀÌ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç°Àº °¨¿° À§Çè¿¡ µû¶ó Áß¿ä, ÁØÁß¿ä, ºñÁß¿ä·Î ºÐ·ùµÇ¾î ÀûÀýÇÑ ¼Òµ¶ °øÁ¤À» ¼±ÅÃÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹Ý¸é, ÀÏȸ¿ë Á¦Ç° À¯ÇüÀº Àç»ç¿ë °¡´ÉÇÑ Á¦Ç°À¸·Î ÀÎÇÑ º´¿ø³» °¨¿° Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀåÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ÀÏȸ¿ë Á¦Ç°Àº À¯Áöº¸¼ö ¹× º¸°ü ºñ¿ëÀÌ ³·±â ¶§¹®¿¡ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¶Áö¸·À¸·Î, ÀÌ Á¦Ç° ºÎ¹®Àº ÀÌÂ÷ ¿À¿°ÀÇ ¹ß»ýÀ» ¾ïÁ¦Çϱâ À§ÇØ Ã¤Åà ¼öÁØÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
¿ëµµº°·Î´Â ÃÖ¼Òħ½À¼º, Ãß°£ÆÇ ¹× ½Å°æÀÇ °¡½Ã¼º Çâ»óÀ¸·Î ÀÎÇØ °¨¾Ð¼úÀÌ 2021³â °¡Àå ³ôÀº ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ´Ù¾çÇÑ ÇüÅÂÀÇ °¨¾Ð¼úÀº ´õ ³ªÀº °á°ú¸¦ °¡Á®¿À°í ÇÕº´ÁõÀ» ÃÖ¼ÒÈÇϱ⠶§¹®¿¡ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ ÀûÀÀÁõ¿¡ »ç¿ëÇÒ ¼ö ÀÖ´Â °¨¾Ð¼ú ¿Ü¿¡µµ ÅðÇ༺ ¿äÃß°ü ÇùÂøÁõÀº ôÃß ÁÖÀ§ ±ÙÀ° À§Ãà ¿¹¹æ, ±ÙÀ° ¹Ú¸® °¨¼Ò, ÈÄÅð µî °¨¾Ð¼úÀÇ ¿©·¯ ÀÌÁ¡À¸·Î ÀÎÇØ 2021³â °¡Àå ³ôÀº ¸ÅÃâ Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.
ÃÖÁ¾ ¿ëµµº°·Î´Â ³»½Ã°æ ¼ö¼úÀÇ ´ë±Ô¸ð äÅðú ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ º´¿ø ºÎ¹®ÀÌ 2021³â °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¹Ý¸é, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ/Ŭ¸®´ÐÀº ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö°í ÀÔ¿ø ±â°£ÀÌ ´ÜÃàµÊ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ºÎ¹®ÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´çÀÏ ¼ö¼úÀÇ Áõ°¡ Ãß¼¼´Â ½ÅÈï °æÁ¦±¹¿¡¼ »ó´çÇÑ ºñ¿ë Àý°¨°ú ÃÖÀûÀÇ ÀÇ·á ¼ºñ½º Á¦°øÀ¸·Î À̾îÁ® ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
2021³â¿¡´Â ºÏ¹Ì°¡ ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. ±× ¹è°æ¿¡´Â ¹ßÀüµÈ ÀÇ·á ÀÎÇÁ¶ó, ÷´Ü ±â¼úÀÇ ³ôÀº µµÀÔ, ÃÖ¼Òħ½ÀÀû Ä¡·áÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº Áß±¹, Àεµ¿Í °°Àº ±¹°¡µéÀÇ Áö¸®Àû È®Àå, ±Þ¼ÓÇÑ °æÁ¦ ¹ßÀüÀ» À§ÇÑ ½ÃÀå Âü¿©ÀÚµéÀÇ ÅõÀÚ Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó °³¼±À¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â Áö¿ªÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀº ³ëÀÎ Àα¸ ºñÀ²ÀÌ °¡Àå ³ôÀº Áö¿ªÀ¸·Î ³ëÀÎ Àα¸ÀÇ Ã´Ãß Áúȯ À¯º´·üÀÌ °¡Àå ³ôÀº Áö¿ªÀ̱⵵ ÇÕ´Ï´Ù.
UBE(Unilateral Biportal Endoscopy) ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ³»½Ã°æ ½Ã°¢È ½Ã½ºÅÛÀÇ ¹ßÀüÀ¸·Î ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 13¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- Àç»ç¿ë °¡´ÉÇÑ Á¦Ç° ºÎ¹®Àº ÷´Ü ¼Òµ¶ ¹× »ì±Õ ±â¼úÀ» ÅëÇÑ ³ôÀº ȸ¼öÀ²·Î ÀÎÇØ 2024³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
- °¨¾Ð ÀÀ¿ë ºÐ¾ß´Â ÃÖ¼Òħ½À¼º°ú ºü¸¥ ȸº¹ ½Ã°£À¸·Î ÀÎÇØ 2024³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
- 2024³â ½ÃÀåÀº ³»½Ã°æ ¼ö¼úÀÇ ´ë±Ô¸ð µµÀÔ°ú ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÏ´Â º´¿ø ºÎ¹®ÀÌ Áö¹èÀûÀ̾ú½À´Ï´Ù.
- ºÏ¹Ì´Â ÀÇ·á ½Ã¼³ÀÇ È®¸³°ú ³»½Ã°æ ±â¼úÀÇ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ 2024³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå UBE(Unilateral Biportal Endoscopy) ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- »óȯ ÇÁ·¹ÀÓ¿öÅ©
- ºÏ¹Ì
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- UBE(Unilateral Biportal Endoscopy) : ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTLE ºÐ¼®
Á¦4Àå UBE(Unilateral Biportal Endoscopy) ½ÃÀå ºÎ¹® ºÐ¼®, Á¦Ç°º°, 2018-2030³â(¹é¸¸ ´Þ·¯)
- Á¤ÀÇ¿Í ¹üÀ§
- Á¦Ç° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â¡¤2030³â
- ºÎ¹® ´ë½Ãº¸µå
- UBE(Unilateral Biportal Endoscopy) ¼¼°è ½ÃÀå, Á¦Ç°º°, 2018-2030³â
- Àç»ç¿ë °¡´É
- Àç»ç¿ë °¡´É ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ÀÏȸ¿ë
- ÀÏȸ¿ë ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
Á¦5Àå UBE(Unilateral Biportal Endoscopy) ½ÃÀå ºÎ¹® ºÐ¼®, ¿ëµµº°, 2018-2030³â(¹é¸¸ ´Þ·¯)
- Á¤ÀÇ¿Í ¹üÀ§
- ¿ëµµ ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â¡¤2030³â
- ºÎ¹® ´ë½Ãº¸µå
- UBE(Unilateral Biportal Endoscopy) ¼¼°è ½ÃÀå, ¿ëµµº°, 2018-2030³â
- °¨¾Ð
- °¨¾Ð ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ¿äºÎ Á߽ɰü ÇùÂø Áõ(LCCS)
- º¯¼º¼º ¿äºÎ ôÃß°ü ÇùÂøÁõ(DLCS)
- ¿äºÎ ôÃß°ü ÇùÂø Áõ
- ¿äºÎ ôÃß°ü ÇùÂøÁõ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- Å»Àå Á¦°Å
- Å»Àå Á¦°Å ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ôÃß ¾ÈÁ¤È
- ôÃß ¾ÈÁ¤È ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ±âŸ
- ±âŸ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
Á¦6Àå UBE(Unilateral Biportal Endoscopy) ½ÃÀå ºÎ¹® ºÐ¼®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â(¹é¸¸ ´Þ·¯)
- Á¤ÀÇ¿Í ¹üÀ§
- ÃÖÁ¾ ¿ëµµ ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â¡¤2030³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ UBE(Unilateral Biportal Endoscopy) ½ÃÀå, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
- º´¿ø
- º´¿ø ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ/Ŭ¸®´Ð
- ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ/Ŭ¸®´Ð ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ±âŸ
- ±âŸ ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
Á¦7Àå UBE(Unilateral Biportal Endoscopy) ½ÃÀå ºÎ¹® ºÐ¼®, Áö¿ªº°, Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â(¹é¸¸ ´Þ·¯)
- Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â¡¤2030³â
- Áö¿ª ½ÃÀå ´ë½Ãº¸µå
- Áö¿ª ½ÃÀå ÇöȲ
- UBE(Unilateral Biportal Endoscopy) ½ÃÀå Á¡À¯À², Áö¿ªº°, 2024³â¡¤2030³â
- ºÏ¹Ì
- ºÏ¹ÌÀÇ UBE(Unilateral Biportal Endoscopy) ½ÃÀå, 2018-2030³â
- ¹Ì±¹
- ij³ª´Ù
- ¸ß½ÃÄÚ
- À¯·´
- À¯·´ÀÇ UBE(Unilateral Biportal Endoscopy) ½ÃÀå, 2018-2030³â
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ³ë¸£¿þÀÌ
- ½º¿þµ§
- µ§¸¶Å©
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- Çѱ¹
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- Äí¿þÀÌÆ®
Á¦8Àå °æÀï ±¸µµ
- ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®, ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷º°
- ±â¾÷ ºÐ·ù
- ±â¾÷ °³¿ä
- Endovision Co. Ltd.
- Karl Storz
- Smith &Nephew
- Stryker Corporation
- CONMED Corporation
- Maxer Endoscopy GmbH
- Joimax GmbH
- Richard Wolf
- Jiangsu Bonss Medical Technology Co. Ltd.
- Kinetix Lifesciences
ksm 24.12.26
Unilateral Biportal Endoscopy Market Growth & Trends:
The global unilateral biportal endoscopy market size is estimated to reach USD 1.35 billion by 2030, expanding at a CAGR of 6.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing demand for minimally invasive surgeries and the growing awareness of the benefits such as reduced hospitalization, minimal collateral tissue damage, reduced postoperative complications, and faster recovery. Moreover, surgeons and their practices are transitioning from conventional open procedures to robotic assisted and visually advanced endoscopic procedures. Furthermore, technology advancements in the field of spinal endoscopic procedures and minimally invasive surgeries are expected to bolster market growth. For instance, June 2017, Olympus introduced 3D surgical endoscope, which is compatible with VISERA ELITE II system. It uses 3D imaging that helps with in depth perception for precision in surgery.
The on-going Covid-19 pandemic has burdened healthcare systems across the globe and has led to significant transformations in the healthcare industry, thereby forcing endoscopy facilities to reduce volumes of elective and non-essential endoscopic procedures. For instance, a survey conducted for endoscopy units across 55 countries by the World Endoscopy Organization between April 2020 and May 2020, reported an 87.0% reduction of in the number of endoscopy procedures. The ongoing pandemic has caused alterations in the operating room structures, workforce, indications, and pre-op setup. The alarming decline in endoscopic procedures was recorded in emerging economies with developing healthcare facilities.
In 2021, the reusable product type segment accounted for the largest revenue share owing to the widespread adoption of these products due to their recoverability rate through disinfection and sterilization. The bifurcation of these products based on the exposure of infection risk into critical, semi-critical, and non-critical devices enables selecting the appropriate disinfection process. On the other hand, single use product type segment is anticipated to register the fastest growth during the forecast period owing to the increasing incidence of hospital acquired infections due to reusable products. In addition, single use products are low on maintenance cost and storage, which is expected to propel the growth of this segment. Lastly, this product segment is witnessing a rise in adoption levels to curb the incidences of cross-contamination.
Based on the application, the decompression segment accounted for the highest revenue share in 2021 owing to its minimally invasive nature and enhanced visualization of discs and nerves is contributing to the growth of this segment. The various forms of decompression procedures provide more favorable outcomes and minimum complications, thereby boosting growth. In addition to decompression techniques available for varied indications, degenerative lumbar canal stenosis recorded the highest revenue share in 2021 owing to the multiple benefits of decompression procedures such as prevention of paraspinal muscle atrophy, reduced muscle dissection, and retraction.
Based on end-user, the hospitals segment accounted for the largest revenue share in 2021 owing to large-scale adoption of these endoscopic procedures and growing demand for minimally invasive surgeries. On the other hand, ambulatory surgery centers/clinics are anticipated to be the fastest growing segment during the forecast period owing to increasing preference for minimally invasive surgeries and reduced hospitalization. The growing trend of same day surgery has resulted in significant cost savings and optimum care delivery in the developed economies and is therefore expected to boost segment growth.
In 2021, North America dominated the market. This can be attributed to developed healthcare infrastructure, high adoption of advanced technologies, and an increase in awareness about the advantages of minimally invasive therapies. On the other hand, Asia Pacific is expected to be the fastest-growing region during the forecast period owing to increasing investments by market players for geographic expansion and rapid economic development in countries such as China and India and improving health infrastructure in this region. Moreover, the prevalence of spinal disorders in the geriatric population is the highest in this region due to the presence of largest proportion of the geriatric population.
Unilateral Biportal Endoscopy Market Report Highlights:
- The market size is anticipated to be valued at USD 1.35 billion by 2030, owing to increasing demand for minimally invasive surgeries and advancements in endoscopic visualization systems
- The reusable product segment dominated the market in 2024 owing to the high recoverability rate with advanced disinfection and sterilization techniques
- The decompression application segment dominated the market in 2024, owing to its minimal invasive nature and quicker recovery time
- The hospital segment dominated the market in 2024 owing to large scale adoption of endoscopic procedures and catering to the rising demand of minimally invasive surgeries
- North America dominated the market in 2024 owing to well-established healthcare facilities and technological advancements in endoscopic techniques
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Segment scope
- 1.1.2. Regional scope
- 1.1.3. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. Research Assumptions
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Application outlook
- 2.2.3. End use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Unilateral Biportal Endoscopy Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. Reimbursement Framework
- 3.3.1. North America
- 3.3.2. Europe
- 3.3.3. Asia Pacific
- 3.3.4. Latin America
- 3.3.5. Middle East & Africa
- 3.4. Unilateral biportal endoscopy: Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.2. PESTLE Analysis
Chapter 4. Unilateral Biportal Endoscopy Market Segment Analysis, By Product, 2018 - 2030 (USD Million)
- 4.1. Definition and Scope
- 4.2. Product Market Share Analysis, 2024 & 2030
- 4.3. Segment Dashboard
- 4.4. Global Unilateral biportal endoscopy Market, by Product, 2018 to 2030
- 4.5. Reusable
- 4.5.1. Reusable market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6. Single-Use
- 4.6.1. Single-use market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Unilateral Biportal Endoscopy Market Segment Analysis, By Application, 2018 - 2030 (USD Million)
- 5.1. Definition and Scope
- 5.2. Application Market Share Analysis, 2024 & 2030
- 5.3. Segment Dashboard
- 5.4. Global Unilateral biportal endoscopy Market, by Application, 2018 to 2030
- 5.5. Decompression
- 5.5.1. Decompression market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.2. Lumbar central canal stenosis (LCCS)
- 5.5.2.1. Decompression market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5.3. Degenerative Lumbar Canal Stenosis (DLCS)
- 5.5.3.1. Degenerative lumbar canal stenosis (DLCS) market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Lumbar Spinal Stenosis
- 5.6.1. Lumbar spinal stenosis market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7. Deherniation
- 5.7.1. Deherniation market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.8. Spinal Stabilization
- 5.8.1. Spinal stabilization market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.9. Others
- 5.9.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Unilateral Biportal Endoscopy Market Segment Analysis, By End Use, 2018 - 2030 (USD Million)
- 6.1. Definition and Scope
- 6.2. End Use Market Share Analysis, 2024 & 2030
- 6.3. Segment Dashboard
- 6.4. Global Unilateral biportal endoscopy Market, by End Use, 2018 to 2030
- 6.5. Hospitals
- 6.5.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6. Ambulatory Surgery Centers/Clinics
- 6.6.1. Ambulatory surgery centers/clinics market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.7. Others
- 6.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Unilateral Biportal Endoscopy Market Segment Analysis, By Region, By Product, By Application, By Ens Use, 2018 - 2030 (USD Million)
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Regional Market Snapshot
- 7.4. Unilateral biportal endoscopy Market Share by Region, 2024 & 2030:
- 7.5. North America
- 7.5.1. North America unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.5.2. U.S.
- 7.5.2.1. U.S. unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.5.3. Canada
- 7.5.3.1. Canada unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.5.4. Mexico
- 7.5.4.1. Mexico unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.6. Europe
- 7.6.1. Europe unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.6.2. UK
- 7.6.2.1. UK unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.6.3. Germany
- 7.6.3.1. Germany unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.6.4. France
- 7.6.4.1. France unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.6.5. Italy
- 7.6.5.1. Italy unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.6.6. Spain
- 7.6.6.1. Spain unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.6.7. Norway
- 7.6.7.1. Norway unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.6.8. Sweden
- 7.6.8.1. Sweden unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.6.9. Denmark
- 7.6.9.1. Denmark unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.7. Asia Pacific
- 7.7.1. Japan
- 7.7.1.1. Japan unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.7.2. China
- 7.7.2.1. China unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.7.3. India
- 7.7.3.1. India unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.7.4. Australia
- 7.7.4.1. Australia unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.7.5. South Korea
- 7.7.5.1. South Korea unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.7.6. Thailand
- 7.7.6.1. Thailand unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.8. Latin America
- 7.8.1. Brazil
- 7.8.1.1. Brazil unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.8.2. Argentina
- 7.8.2.1. Argentina unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.9. MEA
- 7.9.1. South Africa
- 7.9.1.1. South Africa unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.9.2. Saudi Arabia
- 7.9.2.1. Saudi Arabia unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.9.3. UAE
- 7.9.3.1. UAE unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
- 7.9.4. Kuwait
- 7.9.4.1. Kuwait unilateral biportal endoscopy market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company Categorization
- 8.3. Company Profiles
- 8.3.1. Endovision Co. Ltd.
- 8.3.1.1. Company overview
- 8.3.1.2. Financial performance
- 8.3.1.3. Product benchmarking
- 8.3.1.4. Strategic initiatives
- 8.3.2. Karl Storz
- 8.3.2.1. Company overview
- 8.3.2.2. Financial performance
- 8.3.2.3. Product benchmarking
- 8.3.2.4. Strategic initiatives
- 8.3.3. Smith & Nephew
- 8.3.3.1. Company overview
- 8.3.3.2. Financial performance
- 8.3.3.3. Product benchmarking
- 8.3.3.4. Strategic initiatives
- 8.3.4. Stryker Corporation
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Product benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. CONMED Corporation
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Product benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Maxer Endoscopy GmbH
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Product benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Joimax GmbH
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Product benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Richard Wolf
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Product benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Jiangsu Bonss Medical Technology Co. Ltd.
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Product benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. Kinetix Lifesciences
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Product benchmarking
- 8.3.10.4. Strategic initiatives